发现GPCR药物:新的药物,标和适应症
Javier Sánchez Lorente1, Aleksandr V Sokolov2, Gavin Ferguson1,3
1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
G蛋白结合受体 (GPCR) 是主要的药物标,有516种已批准的药物和337种正在临床试验中. 研究表明,在代谢性疾病,瘤学和免疫学中,GPCR药物开发的增加.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
- 生物化学 生物化学
背景情况:
- 由于它们在各种生理和病理过程中的关键作用,G蛋白结合受体 (GPCR) 代表了主要的药物标类.
- 已批准的药物和正在临床研究中的药物广泛针对GPCR超级家族.
研究的目的:
- 分析GPCR超级家族药物发现和开发的当前趋势.
- 提供已批准的GPCR向药物,临床试验候选药物和新兴治疗领域的全面概述.
主要方法:
- 对监管机构批准的药物和针对GPCR向剂的临床试验数据进行系统审查.
- 对药物标,适应症,销售数据和临床试验进展情况的分析.
- 识别新目标和新兴模式,如全调节剂和生物制剂.
主要成果:
- 有516种针对121种GPCR的药物获得批准,占所有批准药物的36%.
- 目前有337种针对133种GPCR的药物,包括30种新型标,正在临床试验中.
- 代谢性疾病,瘤学和免疫学GPCR药物开发的显著增长,糖尿病和肥胖症治疗的市场价值很大.
结论:
- GPCRs仍然是药物发现的高生产率领域,拥有大量批准和研究中的药物.
- 新兴趋势包括专注于新的标,全调节剂,生物制剂,以及在代谢疾病,瘤学和免疫学中扩大应用.
- 未开发的目标疾病关联和途径偏差信号为GPCR药物开发提供了未来的机会.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
相关概念视频
Drug Discovery: Overview
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Preclinical Development: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical,...
GPCRs Regulate Adenylyl Cylase Activity
